Impact Research Institute
Impact Research Institute
Waco, Texas, United States6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Multi-analyte Blood Test Clinical Trial | Digestive System Diseases, Digestive System Neoplasms, Fibrosis, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, cirrhosis of liver, epithelial neoplasm, hepatocellular carcinoma, liver cancer, liver disorder, neoplasm | Recruiting | Not stated | 2026-07-10 | NCT05199259 | |
| Clinical Trial Multi-analyte Blood Test | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Active, not recruiting | Not stated | 2026-07-10 | NCT03694600 | |
| A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder, metabolic dysfunction-associated steatohepatitis | Active, not recruiting | Phase 3 | 2026-07-08 | NCT05500222 | |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-07-02 | NCT04849728 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-06-01 | NCT03900429 | |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Digestive System Diseases, Dyslipidemias, Fibrosis, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, fatty liver disease, hyperlipidemia, hyperthyroxinemia, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, thyroid gland disorder, thyroid hormone resistance syndrome | Active, not recruiting | Phase 3 | 2026-05-27 | NCT04951219 |